Guangzhou Pharmaceut (GZPHF) 2.1985 $GZPHF
Investigation Report on China's Cefathiamidine Market, 2010-2019
M2 - Thu Aug 06, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bg8zn7/investigation) has announced the addition of the "Investigation Report on China's Cefathiamidine Market, 2010-2019" report to their offering. Developed by Guangzhou Baiyunshan Pharmaceutical General Factory, cefathiamidine has been written into the Chinese Pharmacopoeia (2005). Ever since its marketing in 2000, the sales value of cefathiamidine has risen from less than CNY 100 million in 2005 to CNY 459 million in 2014 with CAGR during this period reaching up to 18.6%. Despite its status as the first generation of cephalosporin, cefathiamidine's antimicrobial effect especially that on enterococcus has surpassed all other similar products. As a mature product in the clinic, cefathiamidine has been widely used for the treatment of respiratory, liver, five senses, urinary tract infections, endocarditis and sepsis. Manufacturers of cefathiamidine focus on high-end market and emphasize products' ingenuity and outstanding quality. Currently, the cefathiamidine industry shows a high degree of market concentration. We have Guangzhou Baiyunshan Pharmaceutical General Factory, Shandong Luoxin Pharmacy Stock Co., Ltd, Shandong Lukang Pharmaceutical Co., Ltd, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd and Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd, among which Guangzhou Baiyunshan Pharmaceutical General Factory has the largest market share of 82.33% in 2014 for sales value. As cefathiamidine acts like Methicillin-resistant Staphylococcus aureus (MRSA) and is much safer than traditional drugs for MRSA like vancomycin, norvancomycin, teicoplanin and linezolid, it still has a market potential. The market size of cefathiamidine is expected to keep growing in the next few years in China. Key Topics Covered: 1 Related Concepts of Cefathiamidine 2 Market Profile of Cefathiamidine in China 3 Survey on Sales Status of Cefathiamidine in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Cefathiamidine in China, 2010-2014 5 Survey on Dosage Forms of Cefathiamidine in China, 2010-2014 6 Reference Price of Cefathiamidine in Chinese Hospitals in 2014 7 Major Manufacturers of Cefathiamidine in Chinese Market, 2010-2014 8 Market Outlook of Cefathiamidine in China, 2015-2019 Companies Mentioned - Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. - Baiyunshan Pharmaceutical General Factory - Shandong Luoxin Pharmacy Stock Co., Ltd - Shandong Lukang Pharmaceutical Co., Ltd - Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd - Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/bg...estigation
Chinese Patent Medicine Research and Development Trend Forecasts 2014-2018
M2 - Thu Oct 16, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d5zlrr/research_and) has announced the addition of the "Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018" report to their offering. Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 analyses the policy environment, market scale, competition pattern, development trend and key enterprises in Chinese patent medicine industry in China. The implement of New Medical Reform Plan provides solid guarantee for the development of Chinese patent medicine, but also National Essential Drugs List lists large batch of Chinese Patent Medicine, which drives the continual expansion of Chinese patent medicine market scale in China effectively. In 2009, the cumulative output of Chinese patent medicine was 1.8037 million ton, since 2010, the Chinese patent medicine industry has been maintaining fast growth, the cumulative output was 1.9977 million ton in 2010 and 3.1052 million ton in 2013. With the era development, the health concept has been given new connotation, the third state (Sub-health state) and its harm has cause people's extensive concerns; and with the improvement of living standard, people long for life quality and long life increasingly. Human medical model has been transformed from the pure biomedical model to the biological-psychology-sociological model, and from treatment of disease to the model combining prevention, health, treatment and recovery. The chemical drugs bite off more than they can chew in this field, while the profound Chinese patent medicine are causing people's attention and playing important role in health increasingly, and the rush of health cult provides valuable opportunities and extensive space for Chinese patent medicine development in China. Key Topics Covered: 1. Overview of Chinese Patent Medicine 2. Development Environment of Chinese Patent Medicine in China 3. Current Status of Chinese Patent Medicine Industry in China 4. Analysis and Forecast on Chinese Patent Medicine Market Scale in China 5. Analysis on Import and Export of Chinese Patent Medicine in China 6. Main Chinese Patent Medicine Enterprises in China 7. Future Development Trend of Chinese Patent Medicine in China 8. Expert Suggestion on investment in Chinese Patent Medicine Industry Companies Mentioned - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd - Chongqing Taiji Industry (Group) Co., Ltd - Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd - Jilin Xiuzheng Pharmaceutical Group - Yangtze River Pharmaceutical Group For more information visit http://www.researchandmarkets.com/research/d5...search_and
Investigation Report on China's Cefathiamidine Market, 2010-2019
M2 - Thu Aug 06, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bg8zn7/investigation) has announced the addition of the "Investigation Report on China's Cefathiamidine Market, 2010-2019" report to their offering. Developed by Guangzhou Baiyunshan Pharmaceutical General Factory, cefathiamidine has been written into the Chinese Pharmacopoeia (2005). Ever since its marketing in 2000, the sales value of cefathiamidine has risen from less than CNY 100 million in 2005 to CNY 459 million in 2014 with CAGR during this period reaching up to 18.6%. Despite its status as the first generation of cephalosporin, cefathiamidine's antimicrobial effect especially that on enterococcus has surpassed all other similar products. As a mature product in the clinic, cefathiamidine has been widely used for the treatment of respiratory, liver, five senses, urinary tract infections, endocarditis and sepsis. Manufacturers of cefathiamidine focus on high-end market and emphasize products' ingenuity and outstanding quality. Currently, the cefathiamidine industry shows a high degree of market concentration. We have Guangzhou Baiyunshan Pharmaceutical General Factory, Shandong Luoxin Pharmacy Stock Co., Ltd, Shandong Lukang Pharmaceutical Co., Ltd, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd and Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd, among which Guangzhou Baiyunshan Pharmaceutical General Factory has the largest market share of 82.33% in 2014 for sales value. As cefathiamidine acts like Methicillin-resistant Staphylococcus aureus (MRSA) and is much safer than traditional drugs for MRSA like vancomycin, norvancomycin, teicoplanin and linezolid, it still has a market potential. The market size of cefathiamidine is expected to keep growing in the next few years in China. Key Topics Covered: 1 Related Concepts of Cefathiamidine 2 Market Profile of Cefathiamidine in China 3 Survey on Sales Status of Cefathiamidine in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Cefathiamidine in China, 2010-2014 5 Survey on Dosage Forms of Cefathiamidine in China, 2010-2014 6 Reference Price of Cefathiamidine in Chinese Hospitals in 2014 7 Major Manufacturers of Cefathiamidine in Chinese Market, 2010-2014 8 Market Outlook of Cefathiamidine in China, 2015-2019 Companies Mentioned - Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. - Baiyunshan Pharmaceutical General Factory - Shandong Luoxin Pharmacy Stock Co., Ltd - Shandong Lukang Pharmaceutical Co., Ltd - Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd - Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/bg...estigation
Chinese Patent Medicine Research and Development Trend Forecasts 2014-2018
M2 - Thu Oct 16, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d5zlrr/research_and) has announced the addition of the "Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018" report to their offering. Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 analyses the policy environment, market scale, competition pattern, development trend and key enterprises in Chinese patent medicine industry in China. The implement of New Medical Reform Plan provides solid guarantee for the development of Chinese patent medicine, but also National Essential Drugs List lists large batch of Chinese Patent Medicine, which drives the continual expansion of Chinese patent medicine market scale in China effectively. In 2009, the cumulative output of Chinese patent medicine was 1.8037 million ton, since 2010, the Chinese patent medicine industry has been maintaining fast growth, the cumulative output was 1.9977 million ton in 2010 and 3.1052 million ton in 2013. With the era development, the health concept has been given new connotation, the third state (Sub-health state) and its harm has cause people's extensive concerns; and with the improvement of living standard, people long for life quality and long life increasingly. Human medical model has been transformed from the pure biomedical model to the biological-psychology-sociological model, and from treatment of disease to the model combining prevention, health, treatment and recovery. The chemical drugs bite off more than they can chew in this field, while the profound Chinese patent medicine are causing people's attention and playing important role in health increasingly, and the rush of health cult provides valuable opportunities and extensive space for Chinese patent medicine development in China. Key Topics Covered: 1. Overview of Chinese Patent Medicine 2. Development Environment of Chinese Patent Medicine in China 3. Current Status of Chinese Patent Medicine Industry in China 4. Analysis and Forecast on Chinese Patent Medicine Market Scale in China 5. Analysis on Import and Export of Chinese Patent Medicine in China 6. Main Chinese Patent Medicine Enterprises in China 7. Future Development Trend of Chinese Patent Medicine in China 8. Expert Suggestion on investment in Chinese Patent Medicine Industry Companies Mentioned - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd - Chongqing Taiji Industry (Group) Co., Ltd - Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd - Jilin Xiuzheng Pharmaceutical Group - Yangtze River Pharmaceutical Group For more information visit http://www.researchandmarkets.com/research/d5...search_and
